IP Library Granted Patent US 10,792,246
Granted Patent B2
US 10,792,246 · App. 16/453,679 · Granted Oct 6, 2020

Film formulations containing dexmedetomidine and methods of producing them

Inventors: Vasukumar Kakumanu (Guntur, IN); David Christian Hanley (Brookfield, CT); Frank Yocca (Clinton, CT); Chetan Dalpatbhai Lathia (Woodbridge, CT); Scott David Barnhart (Glen Rock, PA)
Assignees: BIOXCEL THERAPEUTICS, INC.; ARX, LLC
A61K9/0056A61K9/7007A61K31/4174A61K47/34A61K47/38A61P25/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,792,246
App. No.
16/453,679
Granted
Oct 6, 2020
Kind
B2
Abstract

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Claims (43)

1. A self-supporting, dissolvable, mucoadhesive film for sublingual administration comprising:

(i) dexmedetomidine or a pharmaceutically acceptable salt thereof;

(ii) a first water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 40,000 daltons;

(iii) a second water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 140,000 daltons;

(iv) a third water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 370,000 daltons; and

(v) a water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons;

wherein: the only polymers present in the film are water-soluble hydroxypropyl cellulose and water-soluble polyethylene oxide polymers; said first water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 40,000 daltons is present at about 3% to about 8% w/w of the total film weight; said second hydroxypropyl cellulose polymer having a molecular weight of about 140,000 daltons is present at about 3% to about 8% w/w of the total film weight and said third water-soluble hydroxypropyl cellulose polymers having a molecular weight of about 370,000 daltons is present at about 20% to about 40% w/w of the total film weight; said water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons is present at about 50% to about 60% w/w of the total film weight; the polymers in (ii), (iii), (iv) and (v) above together form a single layer film substrate; and

dexmedetomidine or a pharmaceutically acceptable salt thereof is present on one surface of said single layer film substrate.

2. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is dexmedetomidine hydrochloride which is present at a weight ratio of about 0.05 mcg to about 3 mcg for each 100 mcg of total weight of film.

3. A self-supporting, dissolvable, mucoadhesive film for sublingual administration consisting of:

(a) a composition comprising:

(i) dexmedetomidine hydrochloride;

(ii) hydroxypropyl cellulose having a molecular weight of about 40,000 daltons; and

(iii) hydroxypropyl cellulose having a molecular weight of about 140,000 daltons; and

(b) a film substrate comprising:

(i) hydroxypropyl cellulose having a molecular weight of about 40,000 daltons;

(ii) hydroxypropyl cellulose having a molecular weight of about 140,000 daltons;

(iii) hydroxypropyl cellulose having a molecular weight of about 370,000 daltons; and

(iv) polyethylene oxide having a molecular weight of about 600,000 daltons;

wherein the only polymers present in the film are water-soluble hydroxypropyl cellulose and water-soluble polyethylene oxide polymers; hydroxypropyl cellulose having a molecular weight of about 40,000 daltons is present at about 3% to about 8% w/w of the total film weight hydroxypropyl cellulose having a molecular weight of about 140,000 daltons is present at about 3% to about 8% w/w of the total film weight hydroxypropyl cellulose having a molecular weight of about 370,000 daltons is present at about 20% to about 40% w/w of the total film weight and polyethylene oxide having a molecular weight of about 600,000 daltons is present at about 50% to about 60% w/w of the total film weight; and the composition of part (a) is present on the surface of the film substrate (b).

4. The film according to claim 3 , wherein the composition of part (a) constitutes about 0.1% to about 10% w/w of the total film weight.

5. The film according to claim 3 , wherein dexmedetomidine hydrochloride is present at about 0.05% to about 3% w/w of the total film weight.

6. The film according to claim 3 , wherein dexmedetomidine hydrochloride is present at about 0.1% to about 0.2% w/w of the total film weight, hydroxypropyl cellulose having a molecular weight of about 40,000 daltons is present at about 5% w/w of the total film weight and hydroxypropyl cellulose having a molecular weight of about 140,000 daltons is present at about 5% w/w of the total film weight.

7. The film according to claim 3 , wherein the composition of part (a) comprises a colorant and the film substrate of part (b) comprises a colorant, wherein the colorant in part (a) is a different color from the colorant in part (b).

8. The film according to claim 3 , wherein the composition of part (a) covers a portion of the surface of the film substrate of part (b).

9. The film according to claim 1 , wherein the film has a thickness of about 20 micrometers to about 200 micrometers.

10. The film according to claim 1 , wherein the film has a thickness of about 20 micrometers to about 200 micrometers and covers an area (width×length) of about 100 mm 2 to about 300 mm 2 .

11. The film according to claim 1 , wherein the film has a disintegration time of about −14 60 seconds to about 180 seconds.

12. The film according to claim 1 , wherein the film has a mucoadhesion force of about 1000 g to about 2000 g.

13. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is present in an amount of about 10 micrograms.

14. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is present in an amount of about 20 micrograms.

15. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is present in an amount of about 4-0 micrograms.

16. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is present in an amount of about 60 micrograms.

17. A method of treating agitation comprising administering sublingually to the agitated subject a film according to claim 1 .

18. The film according to claim 1 , wherein the film is completely dissolvable in oral mucosal fluid in about 1 minute to about 5 minutes.

19. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is present in an amount of about 90 micrograms.

20. The film according to claim 1 , wherein said dexmedetomidine or a pharmaceutically acceptable salt thereof is present in an amount of about 120 micrograms.

21. The film according to claim 1 , wherein said film is administered in one or more units to provide a total daily dose of dexmedetomidine or a pharmaceutically acceptable salt thereof of about 120 micrograms.

22. The film according to claim 1 , wherein said film is administered in one or more units to provide a total daily dose of dexmedetomidine or a pharmaceutically acceptable salt thereof of about 180 micrograms.

23. The film according to claim 3 , wherein said film is administered in one or more units to provide a total daily dose of dexmedetomidine or a pharmaceutically acceptable salt thereof of about 120 micrograms.

24. The film according to claim 3 , wherein said film is administered in one or more units to provide a total daily dose of dexmedetomidine or a pharmaceutically acceptable salt thereof of about 180 micrograms.

25. The film according to claim 1 , wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is present on one surface of said film substrate and covers a portion of the surface of said film substrate at more than one isolated surface locations.

26. The film according to claim 3 , wherein said composition of part (a) is present on the surface of the film substrate (h) and covers a portion of the surface of said film substrate at more than one isolated surface locations.

Assignments (12)
SECURITY INTEREST Recorded Sep 11, 2024
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 068938/0906 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBERS AND REMOVE APPLICATION NUMBER 17/579,914 AND APPLICATION NUMBER 18/085,263 PREVIOUSLY RECORDED AT REEL: 063789 FRAME: 0539. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 7, 2023
From: ARX, LLC
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 064042/0592 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2023
From: ARX, LLC
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 063789/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2023
From: ARX, LLC
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 062725/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2023
From: ARX, LLC
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 062678/0905 →
SECURITY INTEREST Recorded Apr 19, 2022
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059726/0788 →
SECURITY INTEREST Recorded Apr 19, 2022
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059727/0964 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SIGNATURE PAGE BY ASSIGNEE (CORRECTING ASSIGNEE NAME TO EZ BIOXCEL SOLUTIONS PVT. LTD. RATHER THAN BIOXCEL THERAPEUTICS, INC. PREVIOUSLY RECORDED ON REEL 050021 FRAME 0151. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEE NAME FOR SIGNATURE IS EZ BIOXCEL SOLUTIONS PVT. LTD. Recorded Jan 12, 2021
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 054976/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2019
From: HANLEY, DAVID CHRISTIAN; YOCCA, FRANK; LATHIA, CHETAN DALPATBHAI
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050021/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2019
From: BARNHART, SCOTT DAVID
To: ARX, LLC
Reel/Frame 050021/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2019
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 050021/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2019
From: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050021/0158 →
Continuity (7)
Provisional Application 62690407 · Jun 27, 2018
Provisional Application 62693726 · Jul 3, 2018
Provisional Application 62767422 · Nov 14, 2018
Provisional Application 62787649 · Jan 2, 2019
Provisional Application 62798842 · Jan 30, 2019
Provisional Application 62849747 · May 17, 2019
Related Publication 20200000717A1 · Jan 2, 2020
Cited By (2)
US 12,268,775 US 12,364,683